Trials / Unknown
UnknownNCT05973149
Trial of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
Tolerance, Safety, Pharmacokinetics, and Preliminary Anti-tumor Activity of QLH12016 in Patients With Metastatic Castration Resistant Prostate Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 108 (estimated)
- Sponsor
- Qilu Pharmaceutical Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the tolerance, safety, pharmacokinetics, and preliminary anti-tumor activity of QLH12016 in patients with metastatic castration resistant prostate cancer
Detailed description
Subjects will use QLH12016 for the treatment of mCRPC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QLH12016 | according to the scheme description |
Timeline
- Start date
- 2023-08-31
- Primary completion
- 2025-08-31
- Completion
- 2026-01-01
- First posted
- 2023-08-02
- Last updated
- 2023-08-02
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05973149. Inclusion in this directory is not an endorsement.